Literature DB >> 19047406

Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Dan M Granoff1, Jo Anne Welsch, Sanjay Ram.   

Abstract

Complement factor H (fH), a molecule that downregulates complement activation, binds to Neisseria meningitidis and increases resistance to serum bactericidal activity. We investigated the species specificity of fH binding and the effect of human fH on downregulating rat (relevant for animal models) and rabbit (relevant for vaccine evaluation) complement activation. Binding to N. meningitidis was specific for human fH (low for chimpanzee fH and not detected with fH from lower primates). The addition of human fH decreased rat and rabbit C3 deposition on the bacterial surface and decreased group C bactericidal titers measured with rabbit complement 10- to 60-fold in heat-inactivated sera from human vaccinees. Administration of human fH to infant rats challenged with group B strain H44/76 resulted in an fH dose-dependent increase in CFU/ml of bacteria in blood 8 h later (P < 0.02). At the highest fH dose, 50 microg/rat, the geometric mean number of CFU per ml was higher than that in control animals (1,050 versus 43 [P < 0.005]). The data underscore the importance of binding of human fH for survival of N. meningitidis in vitro and in vivo. The species specificity of binding of human fH adds another mechanism toward our understanding of why N. meningitidis is strictly a human pathogen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047406      PMCID: PMC2632036          DOI: 10.1128/IAI.01191-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

Review 1.  Serologic correlates of protection for evaluating the response to meningococcal vaccines.

Authors:  Paul Balmer; Ray Borrow
Journal:  Expert Rev Vaccines       Date:  2004-02       Impact factor: 5.217

2.  Importance of complement source in measuring meningococcal bactericidal titers.

Authors:  G F Santos; R R Deck; J Donnelly; W Blackwelder; D M Granoff
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

3.  Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.

Authors:  Victor C Hou; Oliver Koeberling; Jo Anne Welsch; Dan M Granoff
Journal:  J Infect Dis       Date:  2005-07-15       Impact factor: 5.226

4.  Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine.

Authors:  Dan M Granoff; Amy Morgan; Jo Anne Welsch
Journal:  Pediatr Infect Dis J       Date:  2005-02       Impact factor: 2.129

5.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine.

Authors:  Jo Anne Welsch; Raffaella Rossi; Maurizio Comanducci; Dan M Granoff
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

7.  Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.

Authors:  W J King; N E MacDonald; G Wells; J Huang; U Allen; F Chan; W Ferris; F Diaz-Mitoma; F Ashton
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

8.  Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Authors:  Synne Sandbu; Berit Feiring; Philipp Oster; Oddveig S Helland; Hilde S W Bakke; Lisbeth M Naess; Audun Aase; Ingeborg S Aaberge; Anne-Cathrine Kristoffersen; Kjersti M Rydland; Sandrine Tilman; Hanne Nøkleby; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

9.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  98 in total

1.  Role of Gonococcal Neisserial Surface Protein A (NspA) in Serum Resistance and Comparison of Its Factor H Binding Properties with Those of Its Meningococcal Counterpart.

Authors:  Lisa A Lewis; Peter A Rice; Sanjay Ram
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.

Authors:  C J Gill; S Ram; J A Welsch; L Detora; A Anemona
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

3.  The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci.

Authors:  Lisa A Lewis; Matthew Carter; Sanjay Ram
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

4.  Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

Authors:  Davide Serruto; Rino Rappuoli; Maria Scarselli; Piet Gros; Jos A G van Strijp
Journal:  Nat Rev Microbiol       Date:  2010-06       Impact factor: 60.633

5.  Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood.

Authors:  Kathleen Y Dunphy; Peter T Beernink; Barbara Brogioni; Dan M Granoff
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

6.  Role of capsule and suilysin in mucosal infection of complement-deficient mice with Streptococcus suis.

Authors:  Maren Seitz; Andreas Beineke; Alena Singpiel; Jörg Willenborg; Pavel Dutow; Ralph Goethe; Peter Valentin-Weigand; Andreas Klos; Christoph G Baums
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

7.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

8.  Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

9.  Binding of human factor H to outer membrane protein P5 of non-typeable Haemophilus influenzae contributes to complement resistance.

Authors:  Jeroen D Langereis; Marien I de Jonge; Jeffrey N Weiser
Journal:  Mol Microbiol       Date:  2014-08-18       Impact factor: 3.501

10.  Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding.

Authors:  Dan M Granoff; Serena Giuntini; Flor A Gowans; Eduardo Lujan; Kelsey Sharkey; Peter T Beernink
Journal:  JCI Insight       Date:  2016-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.